|
|
5-day change | 1st Jan Change | ||
|
151.32 USD |
+1.14% | -1.91% | +4.61% | |
Published on 05/16/2025 at 12:43
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Johnson & Johnson Gets UK Regulatory Approval for Crohn’s Disease, Ulcerative Colitis Drug |
12:43pm |
MT |
|
Uk’s MHRA Approved Guselkumab (Tremfya) To Treat Crohn’S Disease And Ulcerative Colitis |
12:07pm |
RE |
|
France’s Sanofi to invest at least $20 billion in US through 2030 |
May. 14 |
RE |
|
Roche says Trump’s drug price order threatens its $50 billion US investment plans |
May. 14 |
RE |
|
Exclusive-Vietnam cranks up fight on imported counterfeits amid US tariff talks |
May. 13 |
RE |
|
Johnson & Johnson Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10:40 AM |
May. 13 |
|
|
Leerink Partners Downgrades Johnson & Johnson to Market Perform From Outperform, $153 Price Target |
May. 13 |
MT |
|
Equity Markets Higher After US-China Suspend Tariffs |
May. 12 |
MT |
|
Sector Update: Health Care Stocks Climb Monday Afternoon |
May. 12 |
MT |
|
Sector Update: Health Care |
May. 12 |
MT |
|
Top Midday Stories: Shares Rise on US-China 90-Day Trade Ceasefire; Trump Signs Order Targeting High Drug Prices |
May. 12 |
MT |
|
Trump Signs Executive Order Aiming to Lower Drug Prices in US |
May. 12 |
MT |
|
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid US-China Trade Deal |
May. 12 |
MT |
|
Trump’s tariffs and threatened trade actions |
May. 12 |
RE |
|
Wall St set to surge at open as US, China slash tariffs |
May. 12 |
RE |
|
Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices |
May. 12 |
MT |
|
Tryptamine Therapeutics Appoints Herwig Janssen as Non-Executive Chairman; Shares Up 6% |
May. 11 |
MT |
|
Anika Therapeutics Shares Fall After Slump in 1Q Pain-Treatment Sales in U.S. |
May. 09 |
DJ |
|
J&J’s oral psoriasis drug helps patients achieve clear skin in late-stage study |
May. 09 |
RE |
|
J&J’s oral psoriasis drug helps patients achieve clear skin in late-stage study |
May. 09 |
RE |
|
Global markets live: Google, Microsoft, Coinbase, Boeing, IAG… |
May. 09 |
 |
|
J&J: positive phase 3 data in psoriasis |
May. 09 |
CF |
|
Johnson & Johnson Announces New Data from the Phase 3 ICONIC-TOTALa Study Investigating icotrokinra (JNJ-2113) |
May. 09 |
CI |
|
US, UK to Seek Preferential Treatment on Pharmaceutical Tariffs |
May. 09 |
MT |
|
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study |
May. 09 |
MT |
JNJ: Dynamic Chart
Johnson & Johnson is one of the world’s leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13).
The United States accounts for 56.6% of net sales.
More about the company
Buy
Last Close Price
149.61USD
Average target price
169.29USD
Spread / Average Target
+13.15%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
